The Influence of Cytochrome P450 Polymorphisms on Pharmacokinetic Profiles and Treatment Outcomes Among Malaria Patients in Sub-Saharan Africa: A …
Background Sub-Saharan Africa (SSA) population is genetically diverse and heterogenous
thus variability in drug response among individuals is predicted to be high. Cytochrome …
thus variability in drug response among individuals is predicted to be high. Cytochrome …
Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem, A Mårtensson… - Malaria Journal, 2021 - Springer
Background The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
[HTML][HTML] Plasmodium falciparum dhps and dhfr markers of resistance to sulfadoxine–pyrimethamine five years (2016–2020) after the implementation of seasonal …
PVK Tchuenkam, LN Ngum, IM Ali… - Wellcome Open …, 2024 - wellcomeopenresearch.org
Background Antimalarial drug resistance is a major challenge in the fight against malaria.
Cameroon implemented seasonal malaria chemoprevention (SMC) with sulfadoxine …
Cameroon implemented seasonal malaria chemoprevention (SMC) with sulfadoxine …
Population impact of malaria control interventions in the health district of Kati, Mali
A Katile, I Sagara, M Cissoko, CS Bationo, M Dolo… - 2023 - researchsquare.com
Background: WHO and its partners have adopted alternative control interventions since the
failure to eradicate malaria worldwide in the 1960s and 1970s. The aim of these …
failure to eradicate malaria worldwide in the 1960s and 1970s. The aim of these …
[PDF][PDF] Influence of Cytochrome P450 (CYP) 2C8 Polymorphisms on the E cacy and Tolerability of Artesunate-Amodiaquine Treatment of Uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem, A Mårtensson… - scholar.archive.org
Background The antimalarial drug amodiaquine, a commonly used long acting partner drug
in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine …
in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine …